Valery Belakhov Selected Research

Nonsense Codon (Nonsense Mutation)

1/2017	Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
4/2014	Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
3/2014	Long-term nonsense suppression therapy moderates MPS I-H disease progression.
1/2014	Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases.
1/2014	Aminoglycoside-Induced Premature Stop Codon Read-Through of Mucopolysaccharidosis Type I Patient Q70X and W402X Mutations in Cultured Cells.
3/2013	Development of generic immunoassay for the detection of a series of aminoglycosides with 6'-OH group for the treatment of genetic diseases in biological samples.
1/2013	Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression.
12/2012	Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.
1/2012	The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
4/2011	Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Valery Belakhov Research Topics

Disease

10	Inborn Genetic Diseases (Disease, Hereditary) 01/2017 - 05/2009
6	Mucopolysaccharidosis I (Hurler Syndrome) 04/2016 - 05/2009
5	Cystic Fibrosis (Mucoviscidosis) 04/2016 - 05/2009
3	Usher Syndromes (Usher Syndrome) 04/2016 - 05/2009
2	Ototoxicity 04/2014 - 01/2014
2	Lysosomal Storage Diseases (Lysosomal Storage Disease) 03/2014 - 01/2012
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 06/2010 - 05/2009
1	Neoplasms (Cancer) 01/2017
1	Body Weight (Weight, Body) 03/2016
1	Glucose Intolerance 03/2016
1	Visceral Leishmaniasis (Kala Azar) 09/2015
1	Leishmaniasis 09/2015
1	Disease Progression 03/2014
1	Rett Syndrome (Rett's Disorder) 04/2011

Drug/Important Bio-Agent (IBA)

11	Nonsense Codon (Nonsense Mutation)IBA 01/2017 - 05/2009
9	AminoglycosidesIBA 01/2017 - 05/2009
5	Gentamicins (Gentamicin)FDA LinkGeneric 01/2017 - 05/2009
3	DNA (Deoxyribonucleic Acid)IBA 04/2016 - 05/2009
3	Iduronidase (alpha-L-Iduronidase)IBA 03/2014 - 01/2012
2	antibiotic G 418IBA 01/2017 - 03/2013
2	Anti-Bacterial Agents (Antibiotics)IBA 09/2015 - 03/2013
1	Glucose (Dextrose)FDA LinkGeneric 03/2016
1	gamma-Aminobutyric Acid (GABA)IBA 03/2016
1	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 09/2015
1	Proteins (Proteins, Gene)FDA Link 01/2014
1	Biological ProductsIBA 03/2013
1	GlycosaminoglycansIBA 01/2012

Therapy/Procedure

5	Therapeutics 01/2017 - 04/2011